Synairgen (LON:SNG) Hits New 52-Week Low – Here’s Why

Synairgen plc (LON:SNG) shares reached a new 52-week low on Wednesday . The stock traded as low as GBX 0.72 ($0.01) and last traded at GBX 0.93 ($0.01), with a volume of 1287395 shares changing hands. The stock had previously closed at GBX 0.96 ($0.01).

Synairgen Price Performance

The stock’s 50-day moving average is GBX 1.87 and its two-hundred day moving average is GBX 3.22. The company has a market cap of £9.68 million, a P/E ratio of -0.60 and a beta of -2.23.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).